pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include:
● 2 products completed CADTH review, for a total of 9 files under consideration;
● 4 products initiated pCPA negotiations, for a total of 34 active negotiations;
● 2 negotiations completed for a total of 297 completed negotiations;
● No negotiations closed, for a total of 48 closed negotiations; and
● No files closed without negotiations, for a total of 73 declined negotiations.
Files Under pCPA Consideration
2 new drug products received a CDEC recommendation or pERC notification to implement in January 2020, for a total of approximately 9 products* under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Keytruda | Pembrolizumab | Merck Canada | Squamous NSCLC | Conditional |
| Baqsimi | glucagon | Eli Lilly Canada Inc. | Severe hypoglycemic reactions | Conditional |
*Keytruda was initiated in January 2020 and therefore, was not included in the under consideration count.
Negotiation Initiation
The pCPA initiated 4 new negotiations since the last update, for a total of 34 active negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Initiate |
|---|---|---|---|---|---|
| Cimzia | Certolizumab pegol | UCB | Moderate to severe plaque psoriasis | 20 Nov 19 | 56 days |
| Admelog | Insulin lispro | Sanofi | Type 1 and Type 2 Diabetes | N/A | N/A |
| Keytruda | Pembrolizumab | Merck | Squamous NSCLC | 20 Jan 20 | 0 days |
| Xultophy | Insulin degludec/liraglutide | Novo Nordisk | Type 2 Diabetes | 24 Oct 19 | 83 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
Keytruda is now under active negotiations for 5 indications while Cimzia re-enters pCPA negotiations having previously completed an agreement for the Ankylosing Spondylitis and Psoriatic Arthritis indications. While two previous attempts to reach an agreement on Victoza (liraglutide) were unsuccessful, the pCPA will now consider liraglutide in combination with insulin degludec (Tresiba), for which it completed an agreement in July 2018. Finally, negotiations have been initiated for the biosimilar Admelog, which remains under active review by INESSS.
Completed
The pCPA completed 2 negotiations since the last update for a total of 297 completed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Brineura | Cerliponase alfa | Biomarin | Neuronal ceroid lipofuscinosis type 2 | Mar 19 | 306 days |
| Folotyn | Pralatrexate | Servier | Peripheral T-cell lymphoma | Jun 19 | 204 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
